Hypoxia-inducible factor 1 (HIF-1) is a master transcription factor that controls cellular homeostasis.
Introduction
Chemotherapy is the most common systemic treatment for human cancers. Although tumors may initially respond to chemotherapy with partial or even complete remission, they often relapse with more aggressive malignant features such as enhanced angiogenesis and chemoresistance. One principal strategy that tumor cells employ to resist chemotherapy is to highjack and exploit important homeostatic signaling pathways originally used by normal cells to adapt, survive, and reconstruct microenvironment.
Hypoxia-inducible factor-1 (HIF-1), a heterodimer of HIF-1Į and HIF-1ȕ, is such an essential homoeostatic protein (1) . HIF-1 is a master transcriptional activator regulating hundreds of vital genes in all steps of tumorigenesis and tumor progression including angiogenesis (1) , proliferation / apoptosis (2) , therapeutic resistance (1, 3) , cancer stem cell maintenance / reprogramming (4), invasion / metastasis (1), and energy metabolism (5) . More importantly, high HIF-1Į level is an independent prognostic factor for poor chemotherapeutic response, early recurrence, and shortened survival time in many human cancers such as breast cancer (6) . Therefore, there is increasing interest to identify the mechanisms of HIF-1Į upregulation in cancer cells and to develop novel therapeutic strategies targeting HIF-1, thereby enhancing the efficacy of chemotherapy (1) .
Although HIF-1ȕ is constitutively expressed, HIF-1Į is rapidly degraded in proteasome after oxygendependent ubiquitination by the Von Hippel-Lindau protein (pVHL) complex under normoxic conditions. Binding of pVHL depends on hydroxylation of Pro402 and Pro564 in HIF-1Į oxygendependent degradation (ODD) domain. Because this hydroxylation requires HIF prolyl hydroxylase (HIF-PH), O 2 , and iron (7, 8) , hypoxia or iron chelator inhibits ODD-domain prolyl hydroxylation to stabilize HIF-1Į. The stabilized HIF-1Į heterodimerizes with HIF-1ȕ to form HIF-1, which transactivates downstream gene expression such as vascular endothelial growth factor (VEGF). In addition to prolyl hydroxylation, other posttranslational modifications of HIF-1Į such as cysteine Snitrosylation (Cys533) (9) , lysine acetylation (Lys532) (10) , or asparagine hydroxylation (Asn803) in HIF-1Į C-terminal transactivation domain (CAD) by factor inhibiting HIF-1 (FIH-1) (11) also regulate the stability and transcriptional activity of HIF-1Į. Accumulating evidence has proved that hypoxia is one important, but not the only factor stabilizing HIF-1Į. Hypoxia-mimetic drug cobalt chloride, iron chelator, nitric oxide (NO), free radicals, and genetic alterations can enhance HIF-1 expression under normoxic conditions (1, 3, 9, (12) (13) (14) . Doxorubicin (adriamycin) is a first-line chemotherapeutic drug for treating wide spectrum of cancers.
Lee et al elegantly demonstrated that doxorubicin inhibited HIF-1 transcriptional activity by blocking the binding of hypoxia-induced HIF-1 to DNA (15) . HIF-1Į knock-down or inhibition increases the sensitivity of hypoxic tumor cells to doxorubicin (16, 17) . These studies suggest a synergistic anticancer effect by combining chemotherapy with HIF-1 inhibition to target hypoxic tumor cells. In contrast to considerable investigations into the interplay between chemotherapeutic drug and HIF-1Į under hypoxic conditions, so far it is unknown whether chemotherapeutic drugs could regulate HIF-1Į expression under normoxic conditions. One reason for this dearth is the technical difficulty of sensitively detecting HIF-1Į in cells exposed to both normoxia and chemotherapy -two adverse conditions for HIF-1Į expression because of oxygen-dependent HIF-1Į degradation and impaired protein synthesis machinery due to cytotoxicity. To elucidate the effects of chemotherapy on HIF-1Į expression in normoxic tumor cells, we used a 4T1 mouse breast tumor cell line (4T1ODD-luc) which was stably transduced with a fused HIF-1Į reporter gene consisting of mouse HIF-1Į ODD domain and a firefly luciferase (9) . This reporter cell line allows noninvasive monitoring HIF-1Į expression with high sensitivity (9 12 μg/ml (18, 19) and 0 -8 μg/ml (20) , respectively. By treating 4T1ODD-luc and MCF-7 cells with doxorubicin at concentrations within the above ranges, we found increased HIF-1Į expression under normoxic conditions. We then investigated the effects of this normoxic HIF-1Į accumulation on VEGF secretion and tumor angiogenesis after doxorubicin chemotherapy. More importantly, we identified the underlying mechanism which was the activation of the STAT1-iNOS-NO-HIF-1Į signaling pathway.
We also explored therapeutic strategies to suppress doxorubicin-induced normoxic HIF-1Į accumulation.
This work has important implications for trials targeting HIF-1Į, which is upregulated not only by hypoxia but also by chemotherapy. Real-time PCR Total RNA was prepared using the miRVana extraction kit (Applied Biosystems). 1 μg of total RNA was reverse transcribed into cDNA using the iScript cDNA synthesis kit (BioRad).
Materials and Methods

Cell
Real-time PCR was performed on ABI7900HT Fast Real-Time PCR System using Power SYBRGreen
Research. Immunohistochemical Staining 5-6 orthotopic 4T1ODD-luc tumors per group were collected on days 0, 1, 4, 7 and 16. Hypoxia marker pimonidazole (NPI) and perfusion marker Hoechst33342 (SigmaAldrich) were administered as described (14) . 10-μm frozen sections were made. HIF-1Į fluorescent staining was performed with anti-HIF-1Į antibody (Novus). Direct pimonidazole labeling was performed using Hypoxyprobe (NPI) with Zenon Alexa Fluor555 mouse IgG labeling kit (Invitrogen). Statistics Groups were first tested for normality and variance homogeneity. Student t test was applied for two-group comparison. One-way ANOVA Student-Newman-Keuls analysis was applied for pairwise multiple comparisons. Difference was considered significant when P < 0.05.
Results
Doxorubicin increases HIF-1Į level in tumor cells both in vitro and in vivo
To determine whether doxorubicin affects HIF-1Į level in normoxic tumor cells, we treated 4T1ODD- Fig. 2A and B) . The increased HIF-1Į fractions in doxorubicin-treated tumors confirmed the enhanced HIF-1Į reporter activities as described above ( Fig. 1 D and E) . In contrast, there was no difference in either pimonidazole fraction or perfused tumor fraction (Hoechst 33342 labeling) between the doxorubicin-treated tumors and the saline-treated tumors ( Fig. 2C and Supplementary Fig. 2 ). These results suggest that doxorubicin-induced HIF-1Į upregulation was not caused by aggravated tumor hypoxia or decreased perfusion.
Research. 
Doxorubicin-induced HIF-1Į upregulation stimulates VEGF secretion by tumor cells in vitro and tumor angiogenesis in vivo
One important consequence of HIF-1Į upregulation is to form HIF-1 to promote the expression of VEGF -one of the most potent angiogenic factors (1, 2) . Because doxorubicin upregulates tumor cell HIF-1Į both in vitro and in vivo, we asked whether this doxorubicin-induced HIF-1Į may stimulate VEGF secretion by tumor cells and promote tumor angiogenesis. Cell counting demonstrated that the 0.1, 1, and 10 μg/ml doxorubicin treatments significantly reduced surviving cell numbers, which were less than 40% of the control cell numbers at all three time points post-treatment (Fig. 3A) . However, despite a much smaller surviving cell number, the doxorubicin-treated cells secreted at least 87% of the amount of VEGF secreted by the control cells on day 1 (Fig. 3B ). This pattern persisted on days 2 and 3 when, despite < 30% of relative surviving cell number post doxorubicin treatment compared to control treatment, the VEGF secreted by this small fraction of surviving cells was > 60% of the amount of VEGF secreted by the control cells. In other words, the surviving doxorubicin-treated cells secreted an increased amount of VEGF relative to control cells. The other piece of evidence was that 1 μg/ml doxorubicin did lead to higher VEGF secretion than 0.1 μg/ml doxorubicin on both days 1 and 2 ( Fig.   3B ). Therefore, these data support that doxorubicin stimulates VEGF secretion in surviving tumor cells. (Fig. 4B ).
In the control group without doxorubicin, increasing concentrations of L-NAME did not cause any difference in HIF-1Į reporter activity at each time point (Fig. 4B and C) 
significantly increased HIF-1Į reporter activity in the normoxic 4T1ODD-luc cells (Fig. 4B and D empty column). This finding is consistent with the results in Fig. 1A and B. When L-NAME was combined with doxorubicin, the doxorubicin-induced enhancement of HIF-1Į reporter activity was significantly suppressed (Fig. 4D) . We also performed a quantitative WST-1 cell viability assay to compare the surviving fraction of tumor cells at 24, 48, and 72 hours post the above treatments ( Supplementary Fig. 4 ). Statistical analysis revealed that the combination of doxorubicin + L-NAME (0.1, 1, 10 mM) treatments did not increase cell death compared to the treatment with doxorubicin alone ( Supplementary Fig. 4 ). This result rules out increased cell death as a possible cause of decreased HIF-1Į reporter activity in the cells treated with doxorubicin + L-NAME (Fig. 4D) . Therefore, the above experiments suggest that NOS and NO participate in doxorubicin-induced normoxic HIF-1Į accumulation. (Fig. 5A) . Western blots further confirmed that doxorubicin stimulated iNOS protein expression under normoxic conditions (Fig. 5B) . Because STAT1 is a transcription factor required for 
through the phosphorylation of Tyr701 and Ser727 residues (Fig. 5C ). JAK protein family member JAK2 regulates neoplasm, blood cell development, and immune function in response to growth factors and pro-inflammatory cytokines. As an upstream kinase for STAT phosphorylation, JAK2 needs to be activated first by phosphorylation. We performed a Western blot to determine whether JAK2 might be required for the above STAT1 phosphorylation. Because doxorubicin decreases total JAK2 expression and there is no JAK2 phosphorylation after doxorubicin or control treatment ( Supplementary Fig. 5 (Fig. 5D,   Supplementary Fig. 6 A and B) . Western blots further confirmed the doxorubicin-induced upregulations of STAT1 expression and activation were suppressed by EGCG (Fig. 5E ). These results suggest that STAT1-iNOS signaling pathway participates in doxorubicin-induced normoxic HIF-1Į accumulation.
To determine whether inhibition of iNOS could suppress the doxorubicin-induced increase in intracellular NO synthesis, we treated 4T1ODD-luc and MCF-7 cells with doxorubicin in the presence or absence of 1400W. FACS analysis demonstrated that 1400W significantly suppressed the doxorubicin-induced upregulation of NO synthesis in both cell lines (Fig. 6A and B) . To determine whether inhibition of STAT1 could suppress the doxorubicin-induced increase in intracellular NO level, we treated both cell lines with doxorubicin in the presence or absence of EGCG. FACS analysis demonstrated that EGCG also significantly suppressed the doxorubicin-induced upregulation of NO synthesis in both cell lines (Fig. 6C and D) . Because inhibition of either iNOS or STAT1 can suppress doxorubicin-induced NO upregulation, we then sought to determine whether 1400W or EGCG could suppress doxorubicin-induced normoxic HIF-1Į accumulation. Western blots demonstrated that 1400W
and EGCG suppressed doxorubicin-induced HIF-1Į upregulation in both cell lines under normoxic conditions ( Fig. 6E and F) . To verify the role of STAT1 in doxorubicin-induced HIF-1Į upregulation, we knocked down STAT1 by siRNA. STAT1 siRNA decreased 51% of STAT1 expression and 42% of HIF-1Į expression compared to the scrambled siRNA control after doxorubicin treatment ( First, we found that the STAT1-iNOS-NO-HIF-1Į signaling pathway is important for doxorubicininduced normoxic HIF-1Į accumulation (Fig. 7B ). STAT1 is a transcription activator for iNOS expression and NO synthesis (25) . Previous studies have shown that NO enhances the expression and activity of HIF-1Į under normoxic conditions through three mechanisms: 1) NO inhibits prolyl (Fig. 1 and Fig. 4-6 ) and the non-significant difference in activated TAM fractions (TAMmarker CD68 staining) between the doxorubicin-treated tumors and the control tumors in our in vivo study ( Supplementary Fig. 7 ) strongly suggest that the NO synthesized in doxorubicin-treated tumor cells is sufficient to elicit normoxic HIF-1Į accumulation independent of other exogenous NOproducing cells such as TAMs. This work also demonstrates that doxorubicin dosages have different effects on tumor HIF-1 activity. Lee et al elegantly reported that low-dose metronomic doxorubicin therapy (1 mg/kg/day for 5 days) inhibited HIF-1 transcriptional activity in tumor xenografts (15) . The dose of doxorubicin in their metronomic therapy was only 1/10 of the single bolus MTD of doxorubicin (10 mg/kg) in this study. Low-dose metronomic doxorubicin therapy inhibits HIF-1 activity, whereas treatment with doxorubicin at maximum tolerated dose induces HIF-1. Therefore, doxorubicin may play multiple roles to regulate HIF-1 expression and activity depending on dosing, timing, and oxygen tensions. In addition to the above mechanism, previous studies suggest that other important mechanisms may also contribute to doxorubicin-induced normoxic HIF-1Į accumulation: 1) the degradation of HIF- 
1Į depends on HIF-PH, which requires both Fe
2+ and molecular oxygen (7, 8 tumor angiogenesis by activating the STAT1-iNOS-NO-HIF-1Į-VEGF signaling pathway (Fig. 7B) , which is different from those mechanisms underlying HIF-1Į upregulation induced by radiotherapy or hyperthermia (9, 32, 43) . These new findings also suggest the importance of combining conventional chemotherapy such as doxorubicin with anti-VEGF / antiangiogenic therapy to inhibit tumor VEGF secretion and angiogenesis not only caused by hypoxia, but also induced by doxorubicin chemotherapy.
Third, our data indicate that the p53 tumor-suppressor gene may not be required in doxorubicin-induced activation of the STAT1-iNOS-NO-HIF-1Į signaling pathway. P53 mutation is the most common genetic lesion in human cancers. In a previous clinical study, Yamaguchi et al. demonstrated that iNOS expression was significantly correlated with tumor progression by stimulating angiogenesis and there was no correlation between iNOS and p53 expression (44) . The 4T1ODD-luc cell line is p53 null whereas MCF-7 expresses wild-type p53 (45, 46) . The HIF-1Į upregulation in both p53-null and p53
wild-type tumor cell lines indicates that P53 tumor suppressor might not be necessary for doxorubicininduced normoxic HIF-1Į accumulation (Fig. 1C) . In addition, the successful suppression of HIF-1Į upregulation by EGCG or 1400W in both cell lines suggests that the STAT1-or iNOS-targeting strategy does not depend on wild-type p53 expression ( Fig. 6E and F) . Therefore, doxorubicin chemotherapy combined with STAT1 or iNOS inhibitors might be used to treat both p53 wild-type and p53-mutant tumors.
Finally, our findings raise thought-provoking questions about chemoresistance. STAT1 is associated with acquired resistance to doxorubicin (47) . However, the molecular mechanism of STAT1-related therapeutic resistance has not been well understood. Unveiling the activation of the STAT1-iNOS-NO signaling pathway in doxorubicin-induced normoxic HIF-1Į accumulation may provide new insight into (48) . Inhibition of iNOS by 1400W rescues caspase activity and enhances tumor cell chemo-sensitivity (48) . Therefore, iNOS is a key determinant for acquired chemoresistance. Here we discovered that doxorubicin also upregulates iNOS expression and intracellular NO levels ( Fig. 5 and 6 ). Together with Muerkoster's findings, it appears that different types of tumor cells may share this iNOS-NO pathway in response to chemotherapeutic drugs such as doxorubicin and etoposide. Because both doxorubicin and etoposide inhibit topoisomerase II, it is worthwhile to further investigate whether this pathway is a common tumor response to topoisomerase-targeted chemotherapeutic drugs. We also found that 1400W suppressed the expression and activation of STAT1 (Fig. 5E) . One potential possibility might be that 1400W inhibited iNOS and lowered intracellular NO levels, thereby restoring caspase activity in a similar manner found in Muerkoster's study (48) . The restored caspase activity and apoptosis after 1400W treatment might suppress the expression and activation of STAT1. The other potential possibility is based on the finding that NO stimulates STAT1 activation (49) . Therefore, iNOS-specific inhibitor 1400W might attenuate STAT1 activation by suppressing intracellular NO synthesis. It would be intriguing to distinguish and verify the above two hypotheses in future. ± SE). *, P < 0.05; **, P < 0.001, one-way ANOVA. Dox, doxorubicin. AU, arbitrary unit. B, representative bioluminescent images of 4T1ODD-luc cells treated with L-NAME ± Doxorubicin. C, HIF-1Į reporter activity in 4T1ODD-luc cells treated with L-NAME alone (n = 3, mean ± SE). P > 0.05, one-way ANOVA. D, HIF-1Į reporter activity in 4T1ODD-luc cells treated with Dox ± L-NAME (n = 3, mean ± SE). *, P < 0.05, one-way ANOVA. Dox, doxorubicin. 
